"Wellington Partners co-leads an oversubscribed €63 million Series A financing into SciRhom, a preclinical biopharma company that aims to become a leader for treating autoimmune diseases by developing first-in-class anti-iRhom2 antibodies."
Wellington Partners Life Sciences
Wagniskapital- und Private-Equity-Auftraggeber
München, Bayern 1.699 Follower:innen
Info
Since 1998, Wellington Partners has been a leading European Venture Capital firm investing in early- and growth-stage Life Science companies, active in the fields of Therapeutics, Medical Technology, Diagnostics, Digital Health and Industrial Biotechnology.
- Website
-
https://wellington-partners.com/
Externer Link zu Wellington Partners Life Sciences
- Branche
- Wagniskapital- und Private-Equity-Auftraggeber
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- München, Bayern
- Art
- Personengesellschaft (OHG, KG, GbR etc.)
- Gegründet
- 1998
Orte
-
Primär
Wegbeschreibung
Türkenstraße
München, Bayern, DE
Beschäftigte von Wellington Partners Life Sciences
Updates
-
We're #hiring a new Analyst (f/m/d) @ Wellington Partners Life Sciences in Munich, Bavaria. Apply today or share this post with your network.
-
We're #hiring a new Investment Manager (f/m/d) @ Wellington Partners Life Sciences in Munich, Bavaria. Apply today or share this post with your network.
-
Our portfolio company Medical Microinstruments, Inc. just received approval from the US regulatory agency FDA. Sincere congratulations! https://lnkd.in/d38jiN2n.
-
Our portfolio company TRiCares announces the appointment of Ahmed Elmouelhi as the new President & Chief Executive Officer. https://lnkd.in/diGJbMTg
-
Bayer | Pharmaceuticals and Aignostics partner on next generation precision oncology. The strategic multi-year research collaboration is leveraging industry-leading AI/ML algorithms and multimodal patient data to further strengthen Bayer’s oncology portfolio. The goal is to identify novel targets with a strong link to the disease and accelerate clinical development of novel precision therapies for patients living with cancer https://lnkd.in/egQ--KCW
-
Our portfolio company 4SC AG has announced the achievement of another milestone for its lead compound Reminostat (Kinselby). https://lnkd.in/dJx3KdiU
4SC reicht Zulassungsantrag für Resminostat (Kinselby) bei der EMA ein - 4SC AG
4sc.de
-
Today, Medical Microinstruments, Inc. announced a $ 110 Million Series C Financing. The round was led by Fidelity Management And Research Company with significant participation from all existing investors. This largest-ever investment in microsurgery will further MMI’s mission, to transform microsurgery with robotic technology. Read the PR here: https://lnkd.in/d_zcEedC
MMI Raises $110 Million in Series C Financing
businesswire.com
-
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
prnewswire.com